PET

Lantheus’ AI-Enabled aPROMISE Now Available on Siemens Healthineers’ syngo.via platform

Retrieved on: 
måndag, juni 3, 2024
Biomarker, LNTH, PACS, Nuclear medicine, SPECT, Siemens Healthineers, 3D, Communications system, Total, RLT, Clinical professor, Health, Open Archival Information System, Mayo Clinic, Prostate cancer, Molecular imaging, PSMA, SNMMI, European, Oncology, Society, FDA, PET, Quality control, 2D, Medical imaging

Siemens Healthineers’ syngo.via is the vendor-neutral imaging software platform for 2D, 3D, and 4D reading and advanced visualization of medical images.

Key Points: 
  • Siemens Healthineers’ syngo.via is the vendor-neutral imaging software platform for 2D, 3D, and 4D reading and advanced visualization of medical images.
  • The aPROMISE solution will be integrated on the syngo.via platform, one of the leading workstation systems, and will be available via its OpenApps Digital Marketplace.
  • The quantification analysis results provided by aPROMISE are intended to be used as complementary information together with other patient information.
  • The user of aPROMISE shall not rely solely on the information provided by the application for diagnostic or treatment decisions.

Molecular Templates, Inc. Provides Interim Update

Retrieved on: 
måndag, juni 3, 2024
Therapy, IC50, ETB, B cell, Patient, Neck, Cancer, HNSCC, NSCLC, Pharmacodynamics, Tumor microenvironment, CPS, Hematology, COVID, FC, Head, Lung cancer, Plasma cell, PET, CD38, DSM-IV codes, Immunosuppression, Neoplasm, Vaccine

AUSTIN, Texas, June 03, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage company focused on the discovery and development of targeted biologic therapeutics with unique mechanisms of action (engineered toxin bodies or “ETBs”) for cancer and immune-mediated disease, today provided an update on its clinical-stage programs.

Key Points: 
  • AUSTIN, Texas, June 03, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage company focused on the discovery and development of targeted biologic therapeutics with unique mechanisms of action (engineered toxin bodies or “ETBs”) for cancer and immune-mediated disease, today provided an update on its clinical-stage programs.
  • Two heavily pre-treated patients with low PD-L1 expressing squamous cell carcinoma of the head and neck (HNSCC) had achieved partial responses with MT-6402 monotherapy.
  • These patients remain in response and in good clinical condition, continuing treatment in cycles 21 and 12 (one cycle = 4 weeks), respectively.
  • In addition, four of the HNSCC patients treated with MT-6402 had stable disease with two showing tumor reduction.

Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer

Retrieved on: 
torsdag, maj 30, 2024
ASX, PET, Patient, Phase, Docetaxel, PSMA, Safety, Radiation, TLX, ADC, Clutch (eggs), Prostate cancer, RLT, Physician, Quality of life, Pharmaceutical industry

TLX591 is an investigational anti-PSMA1 radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen.

Key Points: 
  • TLX591 is an investigational anti-PSMA1 radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen.
  • Builds on prior data from the ProstACT SELECT2 trial, demonstrating favourable safety profile and biodistribution3.
  • MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive data from the ProstACT SELECT trial (“SELECT”) of TLX591 (177Lu rosopatamab tetraxetan), a lutetium-labelled rADC therapy for the treatment of adult patients with PSMA-positive metastatic castrate-resistant prostate cancer (mCRPC).
  • SELECT is a radiogenomics study intended to evaluate lesion concordance between 68Ga (gallium)-based PSMA-PET4 imaging and TLX591 dosimetry for the purpose of validating PET imaging for patient selection for rADC therapy.

Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer Indicated in Patients With Prostate Cancer

Retrieved on: 
torsdag, maj 30, 2024
Curium, PET, Patient, News, Food, PSMA, FDA, Prostate, Prostate cancer, Cancer, INN, Physician, Nuclear medicine, Medical imaging

Benoit Woessmer, PET Europe CEO at Curium commented, “We are extremely pleased with today’s news that PYLCLARI® is now available to patients with prostate cancer in France.

Key Points: 
  • Benoit Woessmer, PET Europe CEO at Curium commented, “We are extremely pleased with today’s news that PYLCLARI® is now available to patients with prostate cancer in France.
  • PYLCLARI® is being produced in France at Curium’s facilities in Bordeaux, Lyon, Nancy, Marseille, Paris, and Tours.
  • In the U.S., Lantheus received approval for PYLARIFY® (Piflufolastat F 18 Injection) from the Food and Drug Administration (FDA) in May 2021.
  • The European rights were licensed by Curium from Progenics, a Lantheus company, in 2018.

L’OCCITANE en Provence and CARBIOS present a PET bottle made from enzymatic recycling, the result of a European circular economy

Retrieved on: 
torsdag, maj 30, 2024
PET, Partnership, Ellen, PTA, Recycling, MacArthur Foundation, Depolymerization, CO2, MEG, Carreau du Temple, Textile, LCA

The 100% recycled PET bottle from CARBIOS' enzymatic depolymerization process was made with a European value chain committed to responsible consumption of sustainable materials.

Key Points: 
  • The 100% recycled PET bottle from CARBIOS' enzymatic depolymerization process was made with a European value chain committed to responsible consumption of sustainable materials.
  • The bottle’s production began with the local supply of PET waste (already collected, sorted and prepared) to the CARBIOS industrial demonstrator in Clermont-Ferrand, France.
  • Emmanuel Ladent, CEO, CARBIOS : « CARBIOS' innovation accelerates the transition to a circular economy by offering an alternative to petro-sourced PET and a circular PET recycling solution that reduces CO2 emissions by 57%.
  • We're seeing strong demand for high-quality recycled PET which can be used to produce the same applications as with virgin PET.

Global Multimodal Imaging Market Outlook & Forecast 2024-2029: A Fiercely Competitive Landscape with Canon, GE Healthcare, Koninklijke Philips, Siemens Healthineers, and Shimadzu Dominating - ResearchAndMarkets.com

Retrieved on: 
torsdag, maj 30, 2024
Health, Technology, Hospitals, Health Technology, Radiology, Artificial Intelligence, Pharmaceutical, PET, PET/MRI, Patient, Radiation exposure, Biomedical Research, Metabolism, Coronary artery disease, Hospital, Google Images, Ophthalmology, Molecular imaging, Heart failure, Prevalence, Conditional sentence, PET/MR, MRI, Diagnosis, Disease, Drug development, Brain, Echocardiography, Stroke, Gynaecology, Myocardial perfusion imaging, Ageing, AI, Elective surgery, Research, Face, Epilepsy, Tissue, Cardiology, SPECT, Neurology, PET/CT, DSM-IV codes, Shimadzu, Cardiomyopathy, GE HealthCare, Magnetic resonance, Nuclear medicine, Angiography, SPECT/CT, Obstetrics, Perfusion, Siemens Healthineers, Medical imaging

The global multimodal imaging market is dominated by several key players, each with a significant industry presence and a diverse portfolio of imaging solutions.

Key Points: 
  • The global multimodal imaging market is dominated by several key players, each with a significant industry presence and a diverse portfolio of imaging solutions.
  • Some of the leading players in the market include Canon Medical Systems, GE Healthcare, Koninklijke Philips, Siemens Healthineers, and Shimadzu Corporation.
  • The growing adoption of AI and analytics in diagnostic imaging undoubtedly creates exciting opportunities for the multimodal imaging market.
  • The global multimodal imaging market encompasses various end-users, including hospitals, diagnostic imaging centers, research institutions, and others.

Naveris to Present New Data Highlighting Clinical Utility of the NavDx® Test at the 2024 ASCO Annual Meeting

Retrieved on: 
onsdag, maj 29, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Other Science, Medical Devices, Research, Hospitals, Science, Clinical Trials, PET, Induction chemotherapy, Patient, Cancer, PPV, DNA, HNSCC, NPV, Booth, Neck, HPV, TTMV, Recurrence, SCCHN, Neoplasm, Head, OPSCC, MD, Biopsy, ASCO, Woman, Society, Oropharyngeal cancer, Quality of life, CRT, Entrepreneurship, Annual general meeting, Female, Vaccine

"We are pleased to present new data highlighting the high predictive value of TTMV-HPV DNA and its utility in monitoring disease status during treatment.

Key Points: 
  • "We are pleased to present new data highlighting the high predictive value of TTMV-HPV DNA and its utility in monitoring disease status during treatment.
  • These presentations also highlight Naveris’ on-going commitment to patient-centered innovation and collaboration with stakeholders across the cancer care ecosystem.
  • This study evaluates the clinical utility of TTMV-HPV DNA testing in women with HPV-positive oropharyngeal squamous cell carcinoma (OPSCC).
  • Naveris and the NavDx test will be on exhibit at ASCO 2024 at Booth #31142.

Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18), Axumin® (Fluciclovine F 18) and Investigational 18F-Flotufolastat/18F-rhPSMA-7 at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Retrieved on: 
onsdag, maj 29, 2024
Oncology, Health, Clinical Trials, General Health, Radiology, Biotechnology, PET, Blood pressure, Diarrhea, Doctor of Philosophy, Recurrence, Exhibit, Risk, University, SNMMI, FDA, Lymph, Serum, Radiation, Level, MD, ADT, Prostate cancer, PSA, Cancer, Dysgeusia, MedStar Georgetown University Hospital, F 18, Anaphylaxis, Antiandrogen, Medical imaging

Blue Earth Diagnostics invites participants at the 2024 SNMMI Annual Meeting to attend the presentations above and to visit the Company at Exhibit Booth 1639.

Key Points: 
  • Blue Earth Diagnostics invites participants at the 2024 SNMMI Annual Meeting to attend the presentations above and to visit the Company at Exhibit Booth 1639.
  • The Company is hosting a Satellite Symposium, “Let’s Talk about POSLUMA®,” which will discuss the most recent innovations in PSMA-PET imaging for prostate cancer.
  • Blue Earth Diagnostics also has a Medical Affairs information booth at SNMMI, where attendees can learn about the Company’s clinical research.
  • A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence.

Origin Materials and Bachmann Group to Mass Produce PET Caps and Closures

Retrieved on: 
onsdag, maj 29, 2024
Packaging, Recycling, Chemicals, Plastics, Environment, Manufacturing, Sustainability, CO, PET, Partnership, PCO, Automation, Carbon, Bachmann

Origin Materials (“Origin”) (NASDAQ: ORGN, ORGNW), the world’s leading carbon negative materials company with a mission to enable the world’s transition to sustainable materials, and Bachmann Group (“Bachmann”), a leading packaging production and logistics company, announced a strategic partnership to mass produce PET caps and closures.

Key Points: 
  • Origin Materials (“Origin”) (NASDAQ: ORGN, ORGNW), the world’s leading carbon negative materials company with a mission to enable the world’s transition to sustainable materials, and Bachmann Group (“Bachmann”), a leading packaging production and logistics company, announced a strategic partnership to mass produce PET caps and closures.
  • In Bachmann’s existing world-class European manufacturing facilities, Bachmann and Origin will operate the lines to convert virgin and recycled PET into caps, including tethered caps, using high-speed equipment and automation.
  • Origin’s caps are positioned to be the first commercially viable PET closures to reach the mass market.
  • “Bachmann Group will help us produce billions of caps, taking pellet or flake all the way to finished closures.

Loop Industries Collaborates With On and Unveils Launch of the Cloudeasy Cyclon, a Shoe Manufactured With the Infinite Loop(TM) Fiber-To-Fiber Recycling Technology

Retrieved on: 
tisdag, maj 21, 2024
PET, Shoe, Loop, Infinite loop, Sustainability, Carbon, Recycling

This innovative shoe, part of On's Circular Cyclon(TM) program, is a groundbreaking achievement in sustainable footwear, featuring an upper crafted from yarn made with Loop's 100% recycled polyester fiber using the Infinite Loop(TM) fiber-to-fiber recycling technology.

Key Points: 
  • This innovative shoe, part of On's Circular Cyclon(TM) program, is a groundbreaking achievement in sustainable footwear, featuring an upper crafted from yarn made with Loop's 100% recycled polyester fiber using the Infinite Loop(TM) fiber-to-fiber recycling technology.
  • Photo: The Cloudeasy Cyclon shoe, featuring an upper crafted from yarn made with Loop's 100% recycled polyester fiber using the Infinite Loop(TM) fiber-to-fiber recycling technology.
  • This collaboration combines On's commitment to performance and sustainability with Loop's disruptive technology to manufacture a shoe that is not only manufactured with recycled polyester fiber but can also be recycled into new shoes endlessly.
  • The Cloudeasy Cyclon represents a new era of sustainable footwear and sets a precedent for circularity in the industry.